中华全科医师杂志
中華全科醫師雜誌
중화전과의사잡지
CHINESE JOURNAL OF GENERAL PRACTITIONERS
2015年
4期
285-287
,共3页
皮炎,特应性%维生素D3
皮炎,特應性%維生素D3
피염,특응성%유생소D3
Dermatitis,atopic%Vitamin D3
对30例特应性皮炎(AD)患者(观察组)行窄谱中波紫外线(NB-UVB)治疗,另以同期健康志愿者30例为对照组.治疗后,患者欧洲AD评分标准(SCORAD)计分系统和瘙痒程度的视觉模拟尺度(VAS)评分分别为(29.4±9.5)和(3.2±1.1)分,显著低于治疗前[(60.7±11.4)和(6.3±1.6)分](均P＜0.01);ELISA法测定血清25-羟基维生素素D3[25(OH) D3]及1,25-羟基维生素D3[1,25 (OH) 2D3]水平分别为(75.36 ±.23.28) mmol/L和(149.28±46.56) nmol/L,显著高于治疗前的(36.24 ± 18.48) mg/L和(97.68±32.88) nmol/L(均P＜0.01),与对照组的(69.84±20.64) nmol/L和(147.36 ±43.68)nmol/L比较差异无统计学意义(均P＞0.05);治疗前患者血清25 (OH)D3及1,25(OH)2D3水平显著低于对照组(P＜0.01).NB-UVB治疗AD安全有效,能提高血清维生素D3水平.
對30例特應性皮炎(AD)患者(觀察組)行窄譜中波紫外線(NB-UVB)治療,另以同期健康誌願者30例為對照組.治療後,患者歐洲AD評分標準(SCORAD)計分繫統和瘙癢程度的視覺模擬呎度(VAS)評分分彆為(29.4±9.5)和(3.2±1.1)分,顯著低于治療前[(60.7±11.4)和(6.3±1.6)分](均P＜0.01);ELISA法測定血清25-羥基維生素素D3[25(OH) D3]及1,25-羥基維生素D3[1,25 (OH) 2D3]水平分彆為(75.36 ±.23.28) mmol/L和(149.28±46.56) nmol/L,顯著高于治療前的(36.24 ± 18.48) mg/L和(97.68±32.88) nmol/L(均P＜0.01),與對照組的(69.84±20.64) nmol/L和(147.36 ±43.68)nmol/L比較差異無統計學意義(均P＞0.05);治療前患者血清25 (OH)D3及1,25(OH)2D3水平顯著低于對照組(P＜0.01).NB-UVB治療AD安全有效,能提高血清維生素D3水平.
대30례특응성피염(AD)환자(관찰조)행착보중파자외선(NB-UVB)치료,령이동기건강지원자30례위대조조.치료후,환자구주AD평분표준(SCORAD)계분계통화소양정도적시각모의척도(VAS)평분분별위(29.4±9.5)화(3.2±1.1)분,현저저우치료전[(60.7±11.4)화(6.3±1.6)분](균P＜0.01);ELISA법측정혈청25-간기유생소소D3[25(OH) D3]급1,25-간기유생소D3[1,25 (OH) 2D3]수평분별위(75.36 ±.23.28) mmol/L화(149.28±46.56) nmol/L,현저고우치료전적(36.24 ± 18.48) mg/L화(97.68±32.88) nmol/L(균P＜0.01),여대조조적(69.84±20.64) nmol/L화(147.36 ±43.68)nmol/L비교차이무통계학의의(균P＞0.05);치료전환자혈청25 (OH)D3급1,25(OH)2D3수평현저저우대조조(P＜0.01).NB-UVB치료AD안전유효,능제고혈청유생소D3수평.
To explore the clinical efficacies of narrow-band ultraviolet B (NB-UVB) for atopic dermatitis (AD).Thirty AD patients (observation group) and 30 homochromous healthy volunteers (control group) were compared.The post-treatment scores of Scoring AD (SCORAD) and visual analogue scale (VAS) [(29.4 ± 9.5) & (3.2 ± 1.1) points] were lower significantly those pre-treatment [(60.7 ± 11.4) & 6.3 ± 1.6) points] (P ＜ 0.01).The pre and post-treatment serum levels of 25 (OH) D3 and 1,25 (OH)2D3 were detected with enzyme-linked immunosorbent assay (ELISA).The post-treatment serum levels of 25 (OH) D3 and 1,25 (OH) 2 D3 [(75.36 ± 23.28) mmol/L & (149.28 ± 45.56) nmol/L] were significantly higher than those pre-treatment in observation group [(36.24 ± 18.48) mmol/L & (97.68 ± 32.88)nmol/L] (P ＜0.01).There were no significant differences from those in group control[(69.84 ± 20.64) mmol/L & (147.36 ± 43.68) nmol/L] (P ＞ 0.05).And the pre-treatment serum levels of 25 (OH) D3 and 1,25 (OH)2D3 were all significantly lower in observation group than those in control group (P ＜ 0.01).Thus NB-UVB therapy is both safe and effective for AD and it can boost significantly the serum level of vitamin D3.
